新華社通信, ワシントン, 12月 22 (タン・ジンジン記者) 22日, アメリカ. 食品医薬品局は、年齢の大人と子供のCovid-19感染症を治療するために緊急に使用できる最初の経口薬を承認しました 12 軽度から中程度のCovid-19の病気がある年上, 重度の病気のリスクが高い人と同様に.
The US Drug Administration said in a statement that the oral COVID-19 antiviral medicine by Pfizer is called Paxlovid and consists of two antiviral drugs. Patients must take it as soon as possible after the diagnosis of the new crown, and start taking it within 5 days after the appearance of the new crown symptoms, and the continuous use time cannot exceed 5 日々.
The statement said that after evaluating all available scientific evidence, the US Drug Administration believes that Paxlovid may be effective in the treatment of patients with mild to moderate COVID-19, and its known and potential benefits exceed its known and potential risks. Common side effects of this drug may include impaired taste, 下痢, 高血圧, and muscle aches.
Cavazzoni, director of the Center for Drug Evaluation and Research of the US Drug Administration, said that with the emergence of new mutant strains, the prevention and control of the COVID-19 epidemic has entered a critical stage, and the emergency authorization to use this oral drug provides a new tool to combat the COVID-19.
ソース: 新華社通信
